BioPoint is a US-based life sciences consulting organization that brings decades of industry knowledge and expertise to our clients. We offer flexible support whether it is a need for a single resource or our specialized FSP approach, BioPoint can support all facets of drug development. To learn more, please visit https://biopointinc.com/.

Lunit develops AI-powered medical image analysis software via cutting-edge deep learning technology. Our Lunit SCOPE product suite helps researchers and clinicians make accurate and efficient decisions through data-driven imaging biomarkers. Lunit SCOPE IO is our AI-powered analyzer of the tumor microenvironment, purely from H&E, for quantitative immune phenotyping and beyond. Peer reviewed studies employing SCOPE IO have been published in the Journal of Clinical Oncology, Clinical Cancer Research, NPJ Precision Oncology, and more. Lunit SCOPE IHC is our AI-powered analyzer of IHC targets including PD-L1, HER2, and more. Lunit SCOPE IHC currently powers all PD-L1 scoring for Guardant Health’s Galaxy PD-L1 tissue testing. Lunit works with the world’s leading biopharmaceutical companies, CROs, and clinical labs to develop and deploy the next generation of oncology therapeutic biomarkers. For more information, visit https://www.lunit.io/en

As Part of Terumo Medical Care Solutions, the Pharmaceutical Solutions Division develops patient-oriented parenteral delivery solutions for therapeutic performance and safety. Globally trusted for quality and precision, we offer pharmaceutical and medical device manufacturers around the world comprehensive product design and development services. We have decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to product commercialization to optimize critical aspects of parenteral drug delivery. Innovation and creativity are central to our value proposition. Our expert teams lead the industry in developing and manufacturing advanced, high-performing infusion and injection technologies, including CDMO services for all parenteral applications. We listen. We question. We deliver. For more information, visit https://www.terumopharmaceuticalsolutions.com/

Mesa Science Associates is a veteran-owned small business located within the Frederick Innovative Technology Center Inc. (FITCI) in Frederick, MD. Mesa provides a comprehensive array of pharmaceutical development solutions to the research community including the Federal government. From product development planning to NDA or BLA submission, Mesa’s flexible service model leverages a network of highly skilled research and research support professionals from across the United States. This allows Mesa to effectively consult with laboratory specialists concerning pharmacology, preclinical drug evaluation, clinical studies, CMC development, drug delivery system, and regulatory consulting throughout the drug approval process. To learn more, please visit www.mesascience.com.

Datwyler provides high-quality, system-critical elastomer components and has a leading position in the global healthcare market. Within the healthcare solutions business area, Datwyler develops, designs, and manufactures solutions for injectable packaging and drug delivery systems to facilitate customers to create a safer medical environment of tomorrow. Looking back onto more than 100 years of history, Datwyler is a reliable partner, now and in the future! To learn more, please visit https://healthcare.datwyler.com/ 

Veracyte is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Veracyte engages in strategic collaborations with biopharmaceutical researchers to provide comprehensive support for their cancer drug development initiatives. In doing so, we offer a wide range of tools and services to support translational research, clinical development, commercial access, and companion diagnostics. 

LASE Innovation, founded in 2018 and based in Boston, is advancing cell therapy research with their patented LP Cell Barcoding™ technology. LP Cell Barcoding enables massively multiplexed barcoding of cells and the unprecedented ability to connect data across multiple single-cell and omics platforms including flow cytometry, imaging and sequencing. LASE Innovation is developing their flagship LASE Cytometer and LP tagging technology enabling Time-lapse flow™ and Multi-pass flow™ cytometry applications that promise to revolutionize how users approach flow cytometry experiments and researchers connect their data across the myriad of platforms leading to accelerated discoveries for health and disease.

Vivalink offers a Biometrics Data Platform for remote patient monitoring in clinical trials. It combines medical wearable sensors and advanced cloud data services to continuously capture patient vitals and biometrics in virtually any remote setting. Applications include ambulatory cardiac monitoring, neutropenic fever monitoring, and pulmonary hypertension assessment. For more information, go to https://www.vivalink.com/

IMU Biosciences has developed proprietary platform technologies that generate and translate vast system-level immune data into actionable insights and tools to drive the development of precision medicines across a variety of diseases. Built on over a decade of research at King’s College London and the Francis Crick Institute, IMU leverages advanced immune profiling with proprietary AI and machine learning analytics to uncover novel and actionable clinical immune signatures. For more information, visit https://www.imubiosciences.com/

RadMD is a full service, global imaging core lab for Phase 1-Phase 3.  Our oncology focus means expert, responsive teams who move quickly and are adaptable to your program.   Our industry leading reader group, managed by  medical & scientific affairs team continues to set higher standards for quality and innovation to meet demands of clinical development today. For more information, visit https://radmdimaging.com/

Annexin Pharmaceuticals is a publicly listed (NASDAQ/First North, Sweden) clinical stage biotech company advancing ANXV (a human recombinant protein Annexin A5 ) first-in-class biologic with a broad therapeutic potential. The company focus is in ophthalmology and oncology incl ADC. Retinal Vein Occlusion is the primary indication in focus. Here ANXV has a potential to become a first in line first in class treatment. The mode of action is non-overlapping to the current standard of care anti-VEGF. The Phase 2 clinical trial in Retinal Vein Occlusion is approved by the FDA and is currently enrolling in the USA. In immunooncology, the company is advancing ANXV as a monotherapy and as a carrier for chemo (Protein Drug Conjugate). The CMC process is optimized and is being prepared for commercial upscaling. The IP portfolio is strong with the key patents recently issued in major territories. Annexin Pharmaceuticals management are open to looking at the full range of strategic options that would facilitate long term development.